Centre Hospitalier De Libourne Robert Boulin — Clinical Trial Site

19 Registered trials

6 Currently recruiting

Organisation

Centre Hospitalier De Libourne Robert Boulin

Location

Libourne Cedex, France

Identifier

ORG-100029497

Address

112 Rue De La Marne, Bp 199, 33505, France

Departments

cardiology
Département d'hématologie
hématologie
Hematology
Hôpital de jour de médecine
Médecine interne
Medical oncology
Neurologie
Neurology
Oncologie médicale
Oncology-Radiotherapy
Pneumologie
Rhumatologie
Service de Neurologie
Service de Pneumologie

Clinical trials at this site (19)

Search interface

DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Pending

2024-513292-40-00 Multiple sclerosis 5
Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas… Pending

2024-515362-13-00 Philadelphia-negative myeloproliferative neoplasms are 10
DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone re… Pending

2025-521696-31-00 HR+, HER2- breast cancer at high risk of recurrence 6
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Recruiting

2024-517529-26-00 Chronic Inflammatory Demyelinating Polyneuropathy 5 2025-08-04
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p… Recruiting

2024-517325-43-00 multiple myeloma 4 2025-06-19
UVB: treatment of UVeitis in Behçet’s diseases with biologic Recruiting

2024-513371-41-00 Severe uveitis of Behçet’s disease 4 2024-04-25
Preventive effect of Clopidogrel on the systemic sclerosis development risk Recruiting

2024-511005-39-00 Raynaud phenomenon 10 2022-06-22
A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma Recruiting

2024-516181-11-00 RELAPSE/REFRACTORY B-CELL LYMPHOMA. 4 2021-06-10
Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associat… Ended

2024-515433-15-02 acute coronary syndrome 6 2025-01-29
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Follicular Lymphoma 5 2024-05-23
Methotrexate and Metformin in rheumatoid arthritis patients. Ended

2024-511033-35-00 rheumatoid arthritis (RA) 4 2020-12-03
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended

2024-516628-32-00 Multiple Sclerosis 5 2019-01-24
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
Phase III trial of laryngeal preservation comparating chemotherapy followed by radiotherapy to chemotherapy administrated during radiotherap… Ended

2024-513976-16-00 squamous cell carcinomas of the larynx or hypopharynx l 5 2015-06-26
Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted

2024-516687-28-00 Patients with GPA and inadequate response to standard o 5 2025-06-06
A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1… Ended

2023-509001-76-00 Asthma 5 2024-07-01
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended

2023-503693-20-01 Severe eosinophilic asthma 5 2024-04-10
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12